Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu tisková chyba
PubMed
38071169
DOI
10.1016/j.eururo.2023.11.016
PII: S0302-2838(23)03275-X
Knihovny.cz E-zdroje
- Publikační typ
- tisková chyba MeSH
Adelaide and Meath Hospital University College Dublin Belfield Dublin Ireland
Bell Land General Hospital Osaka Japan
Central Clinical Hospital With Outpatient Clinic Moscow Russia
Centre Antoine Lacassagne Université Côte d'Azur Nice France
Centre Hospitalier de l'Université de Montréal Montréal QC Canada
CHU of Québec and Laval University Québec QC Canada
Dnipro State Medical University Dnipro Dnipropetrovsk Oblast Ukraine
Fox Chase Cancer Center Philadelphia PA USA
Georgetown Lombardi Comprehensive Cancer Center Washington DC USA
Merck and Co Inc Rahway NJ USA
Palacký University Medical School and Teaching Hospital Olomouc Czech Republic
Russian Scientific Center of Roentgenology and Radiology Moscow Russia
Sumy Regional Oncology Center Sumy State University Sumy Sumy Oblast Ukraine
Taipei Veterans General Hospital Taipei Taiwan
The Christie NHS Foundation Trust Manchester UK
University Hospital Eberhard Karls University Tübingen Tübingen Germany
Citace poskytuje Crossref.org
